A phase two clinical study on GlaxoSmithKline’s monoclonal antibody treatment against Covid-19 revealed a “potentially important” benefit in reducing respiratory failure in patients aged 70 or older.
Overall, the study, which involved a total of 806 volunteers, showed only a 5% reduction in respiratory failure among all participants dosed with a single dose of the treatment, known as Otilimab, in addition to standard of care, in comparison to those who only received standard of care.
That result was not considered “statistically significant”.
Standard of care was defined as anti-viral treatments and corticosteroids.
However, among the 180 patients aged 70 or older, 65.1% of those who received Otilimab and standard of care were alive and free of respiratory failure 28 days after starting their treatment, against 45.9% for those receiving standard of care alone.
